echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: Risk stratization therapy for infants with acute lymphoblastic leukemia.

    Blood: Risk stratization therapy for infants with acute lymphoblastic leukemia.

    • Last Update: 2020-10-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In clinical practice, children with acute lymphoblastic leukemia (ALL), especially those with KMT2A gene rearfraging (KMT2A-R), had poor prognosis, especially hematopoietic stem cell transplantation (HSCT) with little effect on KMT2A-R infants and young children.
    recently, in the Japanese Pediatric Leukemia/Lymphoma Research Group MRL-10 trial, all infants were divided into three groups: Low Risk (LR), Intermediate Risk (IR) and High Risk (HR) based on KMT2A status, age, and central nervous system leukemia.
    high doses of agarose cytosine in early intensive chemotherapy and HSCT was only performed on children with HR, while micro-disease residues (MRD) were assessed.
    end of the study was a three-year event-free survival rate.
    90 children were involved in the study, including 15 in the LR group, 19 in the IR group and 56 in the HR group.
    in children with KMT2A-R in IR and HR, the three-year event-free survival rate (EFS) was 66.2%, and for children with KMT2A-R in LR, the three-year EFS was 93.32%.
    94.4% of all IRS patients overall, compared with 56.6% of children with HR.
    multi-factor analysis showed that 0.01% of MRD ≥ and early consolidation therapy were associated with poor prognosmation.
    studies have shown that risk stratification and early intensive chemotherapy can reduce low-risk KMT2A gene re-discharge in children for hematopoietic stem cell transplantation, and that the early clearance rate of micro-disease residues is also beneficial for patient prognosis.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.